Involvement of BDNF and NGF in the mechanism of neuroprotective effect of human recombinant erythropoietin nanoforms

Bulletin of Experimental Biology and Medicine

Volumn 155, Issue 2, 2013, Pages 242-244

  Solev, I N ^a   Balabanyan, V Yu ^a   Volchek, I A ^a   Elizarova, O S ^a   Litvinova, S A ^a   Garibova, T L ^a   Voronina, T A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Russian Federation)

Author keywords

BDNF; erythropoietin; poly(butyl)cyanoacrylate nanoparticles; polymerase chain reaction; stroke

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYANOACRYLATE DERIVATIVE; GLYCOLIC ACID; LACTIC ACID; MESSENGER RNA; NANOPARTICLE; NERVE GROWTH FACTOR; POLY(BUTYL)CYANOACRYLATE NANOPARTICLE; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN HEMATOMA; BRAIN HEMORRHAGE; BRAIN LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FRONTAL CORTEX; GENE EXPRESSION; HIPPOCAMPUS; MALE; MORTALITY; NEUROPROTECTION; NONHUMAN; PARTICLE SIZE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CEREBRAL CORTEX; CEREBRAL HEMORRHAGE; CYANOACRYLATES; DRUG DELIVERY SYSTEMS; ERYTHROPOIETIN; HEMATOMA; HIPPOCAMPUS; HUMANS; MALE; NANOPARTICLES; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; RECOMBINANT PROTEINS; STROKE;

EID: 84879976348     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-013-2123-3     Document Type: Article

References (14)

1. T. A. Voronina and R. U. Ostrovskaya, Manual of Experimental (Preclinical) Studies of New Pharmacological Substances [in Russian], Moscow (2005), pp. 253-263.
2. T. L. Garibova, I. P. Galaeva, T. A. Voronina, et al., Eksp. Klin. Farmakol., 66, No. 3, 13-16 (2003).
3. I. A. Dzhindzhikhashvili, V. E. Petrov, V. Yu. Balabanyan, et al., Mol. Med., No. 5, 19-24 (2008).
4. L. Belyaev, L. Khoutorova, W. Zhao, et al., Stroke, 36, No. 5, 1071-1076 (2005).
5. H. Ehrenreich, K. Weissenborn, H. Prange, et. al., Stroke, 40, No. 12, e647-e656 (2009).
6. F. Fumagalli, L. Madaschi, P. Brenna, et al., Eur. J. Pharmacol., 578, No. 1, 19-27 (2007).
7. L. M. Hu, Y. Luo, J. Zhang, et al., Front. Biosc. (Elite Ed.), 3, No. 1, 1541-1555 (2011).
8. J. Kreuter, Specialized Drug Delivery System, ed. P. Tyle, New York (1990), pp. 257-266.
9. J. Kreuter, R. N. Alyautdin, D. A. Kharkevich, and A. A. Ivanov, Brain Res., 674, No. 1, 171-174 (1995).
10. E. Morishita, S. Masuda, M. Nagao, et al., Neuroscience, 76, No. 1, 105-116 (1997).
11. N. S. Santos-Magalhães, A. Pontes, V. M. Pereira, and M. N. Caetano, Int. J. Pharm., 208, Nos. 1-2, 71-80 (2000).
12. A. L. Sirén, M. Fratelli, M. Brines, et al., Proc. Natl. Acad. Sci. USA, 98, No. 7, 4044-4049 (2001).
13. P. Villa, J. van Beek, A. K. Larsen, et al., J. Cereb. Blood Flow Metab., 27, No. 3, 552-563 (2007).
14. S. Wohlfart, A. S. Khalansky, S. Gelperina, et al., PLoS One, 6, No. 5, e19121 (2011).